Correlation of dose with toxicity and tumour response to 90 Y-and 177 Lu-PRRT provides the basis for optimization through individualized treatment planning - Cremonesi, M; Ferrari, ME; Bodei, L (European journal of nuclear medicine and molecular imaging, 2018)
et al.